摘要
目的观察并分析安罗替尼联合白蛋白紫杉醇治疗铂耐药复发性卵巢癌的疗效及安全性,为铂耐药复发性卵巢癌的治疗提供参考。方法选取2021年4月至2022年5月在青岛市市立医院妇科采用安罗替尼联合白蛋白紫杉醇治疗的12例铂耐药复发性卵巢癌患者作为研究对象,接受口服安罗替尼12mg/d,同时给予白蛋白紫杉醇化疗。每1个化疗疗程复查血清肿瘤标记物CA125,每2个化疗疗程复查影像学肿瘤大小变化,同时分析药物的不良反应。结果12例研究对象的平均化疗周期数为6.3个(6~7个)。经过2周期的安罗替尼联合白蛋白紫杉醇化疗后,10例患者的CA125显著下降,经过6周期的治疗后,CA125水平都达到了35U/mL以下;2例患者(1例卵巢透明细胞癌、1例卵巢子宫内膜样癌)的CA125略有下降,但下降不明显。在影像学方面,经过4周期治疗后9例患者病灶缩小程度超过了1/3,经过6周期治疗后,病灶缩小程度大于原来的1/2;1例子宫内膜样癌患者、1例卵巢透明细胞癌患者、1例黏液性癌患者经过6~7周期治疗后病灶直径缩小程度不明显。12例患者中血液性毒性主要表现为白细胞下降,其发生率为100.0%,2例患者3级,1例患者4级,经升白细胞药物处理后降为2级,血小板减少发生率25.0%,血红蛋白减少发生率8.3%;非血液性毒性主要表现为恶心、呕吐,乏力及食欲减退,其发生率100.0%,均为1、2级,高血压的发生率为41.7%,腹泻、肝转氨酶升高发生率为16.7%,蛋白尿发生率8.3%。结论安罗替尼联合白蛋白紫杉醇治疗铂耐药复发性卵巢癌有效率较高,不良反应可控,有望成为治疗铂耐药复发性卵巢癌安全有效的候选方案。
Objective To observe and analyze the efficacy and safety of anlotinib combined with albumin paclitaxel in the treatment of platinum-resistant recurrent ovarian cancer,and to provide a reference for the treatment of platinum-resistant recurrent ovarian cancer.Methods 12 patients with platinum-resistant recurrent ovarian cancer treated with anlotinib combined with albumin paclitaxel in Department of Gynecology,Qingdao Municipal Hospital from April 2021 to May 2022 were selected for the study and received oral anlotinib 12 mg/d and concurrent albumin paclitaxel chemotherapy.Serum tumor marker CA125 was rechecked every chemotherapy course and reviewed imaging changes in tumor size every 2 chemotherapy courses,and simultaneously analyzing adverse reactions of drugs.Results The average number of chemotherapy cycles for the 12 patients with platinum-resistant recurrent ovarian cancer was 6.3(6~7).After 2 cycles of anlotinib combined with albumin paclitaxel chemotherapy,CA125 levels decreased significantly in 10 patients,and after 6 cycles of treatment,CA125 levels has reached below 35 U/mL;CA125 slightly decreased in 2 patients(1 case of ovarian clear cell carcinoma and 1 case of ovarian endometrioid carcinoma),but not significantly.In terms of imaging,after 4 cycles of treatment,the lesion reduction in 9 patients exceeded 1/3,and after 6 cycles of treatment,the degree of lesion reduction was greater than half of the original size.1 case with endometrioid carcinoma,1 case with ovarian clear cell carcinoma,and 1 case with mucinous carcinoma had no significant reduction in the diameter of the lesion after 6~7 cycles of treatment.12 Patients had hematologic toxicity mainly in the form of decreased white blood cells,the incidence of which was 100.0%,2 patients with grade 3 and one patient with grade 4,which was reduced to grade 2 after treatment with leukocyte-raising drugs,the incidence of thrombocytopenia was 25.0%,and the incidence of hemoglobin reduction was 8.3%;non hematological toxicity mainly manifests as nausea,and vomiting,fatigue and decreased appetite,and the incidence was 100.0%,all of which were grade 1 and 2,the incidence of hypertension was 41.7%,the incidence of diarrhea and elevated liver transaminases was 16.7%and proteinuria was 8.3%.Conclusions Anlotinib in combination with albumin paclitaxel has high efficiency and manageable adverse effects in the treatment of platinum-resistant recurrent ovarian cancer,and is expected to be an effective and safe candidate for platinum-resistant recurrent ovarian cancer.
作者
韩宇飞
陆涛
李凤梅
张萍
Han Yufei;Lu Tao;Li Fengmei;Zhang Ping(Department of Gynecology,Qingdao Hospital,University of Health and Rehabilitation Sciences(Qingdao Municipal Hospital),Qingdao Shandong 266011,P.R.China)
出处
《中国计划生育和妇产科》
2023年第7期57-60,67,共5页
Chinese Journal of Family Planning & Gynecotokology
关键词
安罗替尼
白蛋白紫杉醇
铂耐药复发性卵巢癌
疗效
不良反应
anrotinib
albumin paclitaxel
platinum resistant recurrent ovarian cancer
therapeutic effect
adverse reactions
